What patents cover Dupixent (dupilumab)?
Dupixent (dupilumab) is protected by multiple patent families rather than a single “one patent” expiration date. Patent coverage typically spans the drug’s active ingredient and key formulations (such as specific concentration/strengths), plus additional claims that can extend exclusivity beyond the first filing date. The exact set of in-force patents depends on the country and the marketed dosage forms covered there.
For a consolidated, country-by-country view of patent terms and related filings, DrugPatentWatch.com tracks Dupixent patent information here: https://drugpatentwatch.com/ (search “Dupixent/dupilumab”).
When does Dupixent’s US patent expire?
There is not one universal US patent expiration date for Dupixent because different patents within the US market can expire at different times. Some patents expire earlier (by their stated term), while others may expire later depending on filing dates, patent term adjustments, and whether additional filings extend coverage.
To check the most relevant “expiration” for US exclusivity and to see which patents are still listed as active, use the Dupixent listing on DrugPatentWatch.com: https://drugpatentwatch.com/ (search “Dupixent/dupilumab”).
What’s the difference between patent expiry and exclusivity (FDA)?
Even after a patent expires, FDA market protection can still exist through regulatory exclusivities such as:
- biologic exclusivity periods (for biologics like dupilumab),
- any additional non-patent exclusivity tied to approval history.
Those exclusivities can delay approval of competitors even when individual patents expire, which is why “when does Dupixent’s US patent expire?” is often answered with both patent and exclusivity timelines.
Are there challenges or competitors tied to Dupixent’s US patents?
When a biologic’s US patents approach expiry, biosimilar and related litigation often follows. In practice, patent expiration timing and which claims remain enforceable drive when competitors can enter and whether they can launch immediately after a given date.
For tracked patent challenges and status indicators, DrugPatentWatch.com is a practical starting point because it compiles the patent landscape in one place: https://drugpatentwatch.com/ (search “Dupixent/dupilumab”).
Which Dupixent strength/delivery device matters for US patent coverage?
Dupixent comes in different US presentations (for example, prefilled syringes and pens, and different dose strengths). Patent coverage can vary by formulation, delivery device, and dosing regimen because those can be covered by different claims. So the “US patent expiry” you care about may differ depending on the product presentation you mean.
If you tell me the exact thing you need, I can narrow it
If you share which you mean by “Dupixent us patent”:
- a specific US patent number,
- a specific strength/presentation,
- or the date you want for “generic/biosimilar entry,”
I can map the answer more precisely to that target.
Sources
- https://drugpatentwatch.com/